[Significance of transmethylation and S-adenosylmethionine (SAM) in the management of Parkinson's disease with L-dopa].
D000241:Adenosine / Q000008:administration & dosage*; D000368:Aged; D001921:Brain / Q000378:metabolism; D004064:Digestive System / Q000378:metabolism; D004295:Dihydroxyphenylalanine / Q000378:metabolism / Q000627:therapeutic use*; D001068:Feeding and Eating Disorders / Q000139:chemically induced; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006801:Humans; D007273:Injections, Intramuscular; D007275:Injections, Intravenous; D007668:Kidney / Q000378:metabolism; D008297:Male; D008715:Methionine / Q000008:administration & dosage*; D008745:Methylation; D009325:Nausea / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D012436:S-Adenosylmethionine / Q000008:administration & dosage; D014839:Vomiting / Q000139:chemically induced
D004295:Dihydroxyphenylalanine; D012436:S-Adenosylmethionine; D008715:Methionine; D000241:Adenosine
Significato delle transmetilazioni e della S-adenosilmetionina (SAM) nella terapia del morbo di Parkinson con L-dopa.